A Prospective, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedance, in Type 2 Diabetic Subjects With Nephropathy

Phase 2

Completed

• Conditions: Chronic Kidney Disease; Diabetic Nephropathy
• Interventions: Drug: Placebo; Drug: Atrasentan

• Registration Number: NCT01399580
• Lead Sponsor: AbbVie (prior sponsor, Abbott)

Brief Summary

Prospective, Randomized, Double-Blind, Parallel Design, Placebo-Controlled Multicenter Study. The study objectives are to evaluate efficacy and safety, including thoracic bioimpedance, of once daily administration of atrasentan tablets (high dose and low dose) compared to placebo in type 2 diabetic subjects with nephropathy who are receiving the maximum tolerated labeled daily dose of a RAS inhibitor.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2011-07-20
• Study First Submitted QC: 2011-07-20
• Study First Posted: 2011-07-22
• Study Start: 2011-08
• Primary Completion: 2012-09
• Study Completion: 2012-09
• Status Verified: 2013-09
• Disposition First Submitted: 2013-09-25
• Disposition First Submitted QC: 2013-09-25
• Last Update Submitted: 2013-09-25
• Disposition First Posted: 2013-10-25
• Last Update Posted: 2013-10-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 48

Inclusion Criteria

1. Subject is greater than or equal to 18 years old.

2. Subject has type 2 diabetes and has been treated with at least one anti-hyperglycemic medication within the 12 months prior to the Screening Period.

3. Subject is currently receiving an angiotensin converting enzyme inhibitor (ACEi) or Angiotensin II receptor blocker (ARB) (Renin Angiotensin System (RAS) inhibitor).

4. If female, subject is not breastfeeding and is not pregnant (verified by negative serum pregnancy test prior to the Treatment Period). Subject is not of childbearing potential, defined as postmenopausal for at least one year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy) or is of childbearing potential and practicing one of the approved methods of birth control as defined in the Clinical Trial Protocol. Contraception must be used during the study and for 4 weeks after the last dose of study drug.

5. For entry into the Run-in Period the subject must satisfy the following criteria based on the Screening laboratory values:

   • Estimated glomerular filtration rate (eGFR) greater than or equal to 30 and less than or equal to 75 mL/min/1.73m^2 by the Epidemiology Collaboration (EPI) formula
   • Urinary Albumin to Creatinine Ratio (UACR) greater than or equal to 300 and less than or equal to 3500 mg/g as determined by the geometric mean of the two morning void urine specimens obtained at the Screening visit
   • Serum albumin greater than or equal to 3.0 g/dL
   • B-Type Natriuretic Peptide (BNP) less than or equal to 200 pg/mL
   • Negative serum pregnancy test for female subjects
   • Systolic Blood Pressure (SBP) greater than or equal to 110 mmHg and less than or equal to 180 mmHg
   • Glucosylated hemoglobin (HbA1c) less than or equal to 12%

6. For entry into the Treatment Period the subject must satisfy the following criteria based on the last visit of the Run-in Period laboratory values:

   • Renin Angiotensin System (RAS) inhibitor at maximum tolerated labeled dose for the previous 4 weeks with no adjustment of dose
   • Diuretic at any dose unless medically contraindicated (with the exception of loop diuretics greater than or equal to 120 mg QD of furosemide or greater than or equal to 3.0 mg QD of bumetanide or greater than or equal to 150 mg QD of ethacrynic acid or greater than or equal to 60 mg QD of torasemide)
   • UACR ≥ 200 mg/g as determined by the median of the three morning void urine specimens obtained prior to the Week -1 visit
   • Systolic Blood Pressure (SBP) greater than or equal to 110 mmHg and less than or equal to 160 mmHg
   • Serum Potassium less than or equal to 5.5 mEq/L
   • Negative serum pregnancy test for female subjects

Exclusion Criteria

1. Patient has a history of moderate or severe edema, facial edema unrelated to trauma, or a history of myxedema in the prior 6 months to Screening.
2. Subject is receiving loop diuretics greater than or equal to 120 mg QD of furosemide or greater than or equal to 3.0 mg QD of bumetanide or greater than or equal to 150 mg QD of ethacrynic acid or greater than or equal to 60 mg QD of torasemide.
3. Subject has a history of pulmonary edema.
4. Subject has a history of pulmonary hypertension, or any lung diseases requiring oxygen therapy (i.e., chronic obstructive pulmonary disease, emphysema, pulmonary fibrosis).
5. Subject has a history of orthostatic hypotension within the past 6 months as defined by the presence of a supine-to-standing blood pressure decrease greater than or equal to 20 mmHg systolic or greater than or equal to 10 mmHg diastolic within 3 minutes of standing.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Group A - Placebo QD	Placebo	-
Group C - High dose Atrasentan QD	Atrasentan	-
Group B - Low dose Atrasentan QD	Atrasentan	-

Primary Outcome Measures

Name	Time	Method
Change from baseline to each post-baseline visit up to Week 8 in log-transformed Urinary Albumin to Creatinine Ratio (UACR)	Every two weeks for 8 weeks

Secondary Outcome Measures

Name	Time	Method
The change from baseline to each post-baseline assessment of thoracic bioimpedance	Treatment Day 1, Week 1, 2, 4, 6, 8 and 30 days post-treatment
Change from baseline to each post baseline measure for estimated glomerular filtration rate (eGFR)	Every two weeks for 8 weeks

Trial Locations

Locations (28)

Site Reference ID/Investigator# 56927; 🇺🇸 Azusa, California, United States

Site Reference ID/Investigator# 70173; 🇺🇸 Los Angeles, California, United States

Site Reference ID/Investigator# 55543; 🇺🇸 Flushing, New York, United States

Site Reference ID/Investigator# 64023; 🇺🇸 Albany, New York, United States

Site Reference ID/Investigator# 68982; 🇺🇸 Pontiac, Michigan, United States

Site Reference ID/Investigator# 54164; 🇺🇸 Fargo, North Dakota, United States

Site Reference ID/Investigator# 68986; 🇺🇸 Augusta, Georgia, United States

Site Reference ID/Investigator# 54116; 🇺🇸 North Richland Hills, Texas, United States

Site Reference ID/Investigator# 54129; 🇺🇸 Baton Rouge, Louisiana, United States

Site Reference ID/Investigator# 54108; 🇺🇸 Dallas, Texas, United States

Site Reference ID/Investigator# 56644; 🇺🇸 Chicago, Illinois, United States

Site Reference ID/Investigator# 58144; 🇺🇸 Phoenix, Arizona, United States

Site Reference ID/Investigator# 61742; 🇺🇸 Pittsburg, Pennsylvania, United States

Site Reference ID/Investigator# 58153; 🇺🇸 Houston, Texas, United States

Site Reference ID/Investigator# 54110; 🇺🇸 Houston, Texas, United States

Site Reference ID/Investigator# 71034; 🇺🇸 Tempe, Arizona, United States

Site Reference ID/Investigator# 70793; 🇺🇸 Azusa, California, United States

Site Reference ID/Investigator# 56924; 🇺🇸 Boynton Beach, Florida, United States

Site Reference ID/Investigator# 54123; 🇺🇸 Bethlehem, Pennsylvania, United States

Site Reference ID/Investigator# 64027; 🇺🇸 Chula Vista, California, United States

Site Reference ID/Investigator# 54120; 🇺🇸 Concord, California, United States

Site Reference ID/Investigator# 56642; 🇺🇸 Hollywood, Florida, United States

Site Reference ID/Investigator# 64026; 🇺🇸 La Mesa, California, United States

Site Reference ID/Investigator# 58147; 🇺🇸 Willoughby Hills, Ohio, United States

Site Reference ID/Investigator# 54126; 🇺🇸 Greenville, Texas, United States

Site Reference ID/Investigator# 54132; 🇺🇸 Chattanooga, Tennessee, United States

Site Reference ID/Investigator# 54173; 🇺🇸 Silverdale, Washington, United States

Site Reference ID/Investigator# 54121; 🇺🇸 Denver, Colorado, United States